Accessibility StatementSkip Navigation Collaboration will leverage AI-powered neural analysis and Compass' expertise in psychedelic drug development to advance new therapies for mental health KEARNY, N.J., Oct. 30, 2025 /PRNewswire/ -- NeuroKaire, a pioneer in precision psychiatry and neurology, has launched an R&D collaboration with Compass Pathways, a leading biotechnology company dedicated to transforming mental health care. This collaboration aims to deepen the mechanistic understanding of psychedelic c ...

Key Takeaways Tempus AI's Genomics revenues jumped 115% year over year, driven by testing growth and acquisitions. Exact Sciences' genomics advances include Oncotype DX and Oncodetect validation in colorectal cancer. EXAS offers a stronger earnings outlook and valuation appeal, while TEM leads in share performance. Per multiple sources, the integration of genomics into cancer care has transformed treatment approaches, moving away from uniform therapies to precision medicine, where clinical decisions are tai ...

合作概述 - 礼来与英伟达合作构建制药行业最强大的超级计算机和人工智能工厂以加速药物发现和开发 [1] - 该合作旨在利用人工智能缩短新药上市时间并降低药物发现和开发各阶段的成本 [2] - 超级计算机和人工智能工厂预计于12月完成建设并于次年1月上线 [3] 技术细节与能力 - 超级计算机由礼来拥有和运营采用超过1000块英伟达Blackwell Ultra GPU并通过高速网络连接 [5] - 人工智能工厂将用于大规模开发训练和部署用于药物发现和开发的人工智能模型 [5] - 该超级计算机被描述为一种新型科学仪器使科学家能够进行前所未有的大规模研究 [6] - 科学家将能够在数百万次实验上训练人工智能模型以测试潜在药物从而极大扩展药物发现的范围和复杂性 [6] 平台与数据共享 - 礼来推出Lilly TuneLab人工智能和机器学习平台允许生物技术公司访问其基于多年专有研究训练的药物发现模型 [7] - 礼来用于训练模型的专有数据价值10亿美元 [7] - 生物技术公司可通过贡献自身研究和数据来换取模型访问权限平台采用联邦学习技术各方无需直接共享数据 [9] 战略目标与行业影响 - 合作主要机遇在于发现新分子预计相关效益将在2030年显现 [3][7] - 礼来计划利用超级计算机缩短药物开发时间使治疗方法更快惠及患者 [9] - 新科学人工智能代理可支持研究人员先进医学成像技术有助于科学家更清晰了解疾病进展并开发用于个性化护理的新生物标志物 [10] - 合作旨在实现精准医学的承诺即根据个人基因环境和生活方式差异定制疾病预防和治疗方法 [11]

GeneDx (NasdaqGS:WGS) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Company ParticipantsBryan Dechairo - COOKevin Feeley - CFOKatherine Stueland - CEO and PresidentSubbu Nambi - Director of Equity Research DepartmentSabrina Dunbar - Head of Investor RelationsConference Call ParticipantsDavid Westenberg - Senior Research Analyst and Managing DirectorKeith Hinton - Director and Equity Research AnalystTycho Peterson - Managing Director and Research AnalystMark Massaro - Managing Director and Life Science ...

GeneDx (NasdaqGS:WGS) Q3 2025 Earnings Call October 28, 2025 08:30 AM ET Speaker4Good day, and thank you for standing by. Welcome to the GeneDx third quarter 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question during the session, you'll need to press star one-one on your telephone. You will then hear an automated message advising your hand is raised. To start a question, please ...

Oct 28, 2025 8:30 AM Eastern Daylight Time Tempus to Participate in the Stifel 2025 Healthcare Conference Share CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced that it will participate in the Stifel 2025 Healthcare Conference on Thursday, November 13 in New York City. Jim Rogers, Chief Financial Officer at Tempus, will participate in a fireside chat at 10:00 AM ET. The live webcast will be available through the events page ...

GeneDx (Nasdaq: WGS) 3Q 2025 Earnings Presentation October 28, 2025 Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our future performance and our market opportunity, including our expected full year 2025 reported revenue, growth in exome and genome revenue and volume, adjusted gross margin and a ...

Oct 28, 2025 6:30 AM Eastern Daylight Time GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights Share GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third quarter of 2025. "GeneDx's accelerated growth reflects more than business momentum - it's proof of the profound impact we're making for families navigating rare disease and the broader tran ...

Oct 28, 2025 6:30 AM Eastern Daylight Time GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights Share GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third quarter of 2025. "GeneDx's accelerated growth reflects more than business momentum - it's proof of the profound impact we're making for families navigating rare disease and the broader tran ...

Accessibility StatementSkip Navigation SOUTH SAN FRANCISCO, Calif., Oct. 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events. Citi's 2025 SMID Cap Biopharma Call SeriesThursday, November 6, 2025 at 12:00 PM ET Fireside chat with Yujiro S. Hata, President and Chief Executive Officer, hosted by Yigal D. Nochomovitz, Ph. ...